購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
huSTEAP1 Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
huSTEAP1 Mouse
製品名
huSTEAP1 Mouse
製品ID
C002044
系統名
C57BL/6NCya-Steap1tm1(hSTEAP1)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「huSTEAP1 Mouse(カタログ番号C002044)はサイアジェンから購入しました。」と引用してください。
HUGO-GT Humanized Models
Tumor Target Humanized Mouse Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
HUGO-GT Humanized Models
Tumor Target Humanized Mouse Models
基本情報
関連リソース
基本情報
遺伝子名
遺伝子別名
STEAP, PRSS24
NCBI ID
染色体
Chr 7
MGI ID
さらに
系統詳細
STEAP1 (Six transmembrane epithelial antigen of the prostate 1) is a member of the six-transmembrane epithelial antigen family encoded by the STEAP1 gene and is primarily localized on the cell membrane surface. STEAP1 is highly expressed in multiple solid tumors, including prostate cancer, Ewing sarcoma, bladder cancer, and lung cancer, while its expression in normal tissues is relatively restricted [1-3]. STEAP1 is involved in biological processes including cell proliferation, redox homeostasis, and regulation of the tumor microenvironment, and has been associated with tumor invasion, metastasis, and poor prognosis in multiple malignancies [2-4]. Due to its tumor-associated high expression pattern and membrane localization, STEAP1 is considered an important target for cancer immunotherapy. Studies involving STEAP1-targeted monoclonal antibodies, antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and CAR-T/CAR-NK cell therapies have been reported [3-5].
The huSTEAP1 mouse is a humanized model generated by replacing the sequence of exons 2 to 5 in the murine Steap1 gene with the corresponding sequence of human STEAP1 exons 2 to 5. This model is suitable for evaluating the in vivo efficacy and safety of STEAP1-targeted therapeutics, including monoclonal antibodies, ADCs, TCEs, and CAR-T/CAR-NK cells. Furthermore, it is applicable to research on the pathogenesis of prostate cancer and other STEAP1-overexpressing tumors, as well as studies on the tumor immune microenvironment and combination therapy strategies.
参考文献
Gomes IM, Maia C J, Santos C R. STEAP proteins: from structure to applications in cancer therapy[J]. Molecular Cancer Research, 2012, 10(5): 573-587.
Ihlaseh-Catalano S M, Drigo S A, de Jesus C M N, et al. STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma[J]. Histopathology, 2013, 63(5): 678-685.
Yee N S, Zhang S, He H Z, et al. STEAP1: potential therapeutic target for prostate cancer and other cancers[J]. Pharmacology & Therapeutics, 2024, 254: 108517.
Kwon E D, Lee M J, Wang Y, et al. Targeting STEAP1 for cancer immunotherapy[J]. Nature Communications, 2023, 14(1): 2458.
Maia C J, Socorro S, Schmitt F, et al. STEAP1 is over-expressed in human prostate cancer and down-regulated by post-transcriptional mechanisms[J]. The Prostate, 2008, 68(13): 1426-1434.
系統作製戦略
The region from exon 2 to exon 5 of the mouse Steap1 was replaced with the region from exon 2 to exon 5 of the human STEAP1, with the humanized region encompassing both terminal UTRs.

Figure 1. Gene editing strategy of huSTEAP1 mice.
適用分野
Screening, development, and preclinical evaluation of STEAP1-targeted therapeutics;
Immunotherapy research for prostate cancer and other solid tumors;
Studies on the tumor immune microenvironment and combination therapy strategies.
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
